Four cups of coffee daily may help cure colon cancer

Image
Press Trust of India Boston
Last Updated : Aug 18 2015 | 1:57 PM IST
Drinking four or more cups of coffee daily may significantly prevent the return of colon cancer after treatment and improve the chances of a cure, a large new study has claimed.
The research is the first to study an association between caffeinated coffee and risk of colon cancer recurrence, researchers said.
The patients, all of them treated with surgery and chemotherapy for stage III colon cancer, had the greatest benefit from consuming four or more cups of coffee a day (about 460 milligrammes of caffeine).
These patients were 42 per cent less likely to have their cancer return than non-coffee drinkers, and were 33 per cent less likely to die from cancer or any other cause.
Two to three cups of coffee daily had a more modest benefit, while little protection was associated with one cup or less, the researchers said.
The study included nearly 1,000 patients who filled out dietary pattern questionnaires early in the study, during chemotherapy and again about a year later.
"We found that coffee drinkers had a lower risk of the cancer coming back and a significantly greater survival and chance of a cure," said Charles Fuchs, director of the Gastrointestinal Cancer Centre at Dana-Farber Cancer Institute in Boston.
Most recurrences happen within five years of treatment and are uncommon after that, he noted.
In patients with stage III disease, the cancer has been found in the lymph nodes near the original tumour but there are no signs of further metastasis. Fuchs said these patients have about a 35 per cent chance of recurrence.
However, Fuchs is hesitant to make recommendations to patients until the results are confirmed in other studies.
A number of recent studies suggested that coffee may have protective effects against the development of several kinds of cancer, including reduced risks of postmenopausal breast cancer, melanoma, liver cancer, advanced prostate cancer.
Fuchs said the research focused on coffee and other dietary factors because coffee drinking - in addition to possibly being protective against some cancers - had been shown to reduce the risk of type 2 diabetes.
In analysing the results of the new study, Fuchs and his colleagues discovered that the lowered risk of cancer recurrence and deaths was entirely due to caffeine and not other components of coffee.
He said it's not clear why caffeine has this effect and the question needs further study.
One hypothesis is that caffeine consumption increases the body's sensitivity to insulin so less of it is needed, which in turn may help reduce inflammation - a risk factor for diabetes and cancer, Fuchs said.
The study was published in the Journal of Clinical Oncology.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 18 2015 | 1:57 PM IST

Next Story